Integrated Biopharma Inc (INBP) Fair Value & Analysis
Consumer Defensive · US · Market cap $5.9M · ISIN US45811V1052
Integrated Biopharma Inc
INBP · US
Strengths
Risks
Fair value as of: Aug 22, 2026
From 23 valuation models · updated 7 days ago
Share price +12.5% over the past month.
A solid business, trading 67% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price is below even our cautious bear case ($0.4100). The market is more pessimistic than our downside scenario.
- Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range $0.1500 – $1.22 · fair‑value band $0.4100 – $0.6800 · the $0.1800 price screens below the $0.5500 fair value. Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Integrated Biopharma Inc (INBP) currently trades at $0.1800, while our model-based Fair Value estimate is $0.5500, implying the stock looks roughly 205.6% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Integrated Biopharma Inc generated revenue of $48.3M at a net margin of -3.4%. Revenue declined 27.5% year over year. It earns a return on equity of -8.4%. Net debt stands at $3.4M. Fundamentals as of Aug 22, 2026
Our scenario range runs from $0.4100 (bear case) to $0.6800 (bull case); at $0.1800, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -25% fair-value upside, at 206%, INBP screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: DCF Models ($0.7300) versus Earnings-Based ($0.4100). Highest evidence: Growth DCF (80).
Notify me when INBP reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 23
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines.
Full company description
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Integrated Biopharma Inc reported revenue of $54.4M in FY2025 versus $63.6M in FY2021, a compound −3.8%/yr. Reported net income was $808K in FY2025, compounding −43.6%/yr from FY2021.
Watch INBP: get an alert when its fair value changes →
Peer Group
Packaged Foods · 675 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaged Foods median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NESN | CHF 78.52 | CHF 57.26 | -27% |
| Danone S.A BN | €64.70 | €48.41 | -25% |
| Nestlé India Limited NESTLEIND | ₹1,478 | ₹251.94 | -83% |
| The Kraft Heinz Company KHC | $25.13 | $24.59 | -2% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥35.05 | ¥21.93 | -37% |
| Inner Mongolia Yili Industrial Group 600887 | ¥25.51 | ¥32.50 | +27% |
| Yihai Kerry Arawana Holdings 300999 | ¥25.28 | ¥9.89 | -61% |
| General Mills, Inc GIS | $40.44 | $28.32 | -30% |
| Wilmar International Limited F34 | 3.64 SGD | 3.89 SGD | +7% |
| McCormick & Company MKCV | $55.65 | $43.29 | -22% |
Compare Integrated Biopharma Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Integrated Biopharma Inc (INBP) overvalued or undervalued?
What is the fair value of INBP?
What is the quality score of INBP?
What is the revenue of Integrated Biopharma Inc (INBP)?
What is the net profit margin of INBP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Integrated Biopharma Inc in the live analysis
One click puts Integrated Biopharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.